Listed times are in Central European Time (CEST)

WELCOME TO DAY ONE

Introduction: Steve Wedge

Session 1: Targeting RAS

Session Chair: Steve Wedge

Hitoshi Iikura Chugai Pharmaceutical Co. Ltd, Yokohama, Japan

The development of cyclic peptides and the discovery of the LUNA18 RAS inhibitor

Q&A 13:25-13:40

Jan Smith Revolution Medicines, California, USA

Targeting the active (GTP-bound) forms of RAS

Q&A 14:00-14:15

REFRESHMENT BREAK

Session 2: Molecular Glues

Session Chair: Susan Critchlow

Alessio Ciulli University of Dundee / Amphista Therapeutics, Dundee, UK

How PROTAC degraders work: Molecular recognition and design principles

Q&A 14:50 - 15:05

Saverio Alberti Università di Messina, Messina, Italy

Proffered Paper 1: Hu2G10 antibody-drug conjugates target cleaved-activated Trop-2 in cancer cells and show therapeutic efficacy in vivo

Q&A 15:15-15:25

Romi Gupta The University of Alabama at Birmingham, Birmingham, USA

Proffered Paper 2: ATAD2 is a driver and a therapeutic target in ovarian cancer

Q&A 15:35-15:45

REFRESHMENT BREAK

Session 3: Targeting mutant p53

Session Chair: Mark Pearson

Ecaterina E Dumbrava MD Anderson Cancer Centre, Texas, USA

p53 Y220C inhibitor

Q&A 16:20 - 16:35

POSTER SPOTLIGHTS

2 top abstracts presented as 3-minute flash talks

TRANSITION BREAK

VIRTUAL POSTER SESSION

Listed times are in Central European Time (CEST)

WELCOME TO DAY TWO

Session 4: PROTAC degraders

Session Chair: Susan Critchlow

Nicolas Thoma FMI, Switzerland

Oncogenic transcription factors – how they work (and how to get rid of them)

Q&A 14:25-14:40

Elisa Rioja Blanco ETH Zurich, Zurich, Switzerland

Proffered Paper 3: Terbium-161 radioimmunotherapy as an innovative treatment for CD30+ lymphomas

Q&A 14:50 - 15:00

REFRESHMENT BREAK

Session 5: Phenotypic screening

Session Chair: Mark Pearson

Nunki Hassan University of Sydney, Sydney, Australia

Proffered Paper 4: Targeting PAR1 for leukemic stem cell eradication: a promising new treatment strategy for blood cancers

Q&A 15:25 - 15:35

Aimee Iberg Recursion, Salt Lake City, USA

Unbiased phenotypic screening to discover next generation therapies

Q&A 15:55 - 16:10

REFRESHMENT BREAK

Session 6: Antibody - drug conjugates and reactivation of wild-type p53

Session Chair: Erica Jackson

Puja Sapra SVP, Biologics Engineering and Oncology Targeted Discovery, AstraZeneca, Gaithersburg, US

The renaissance of ADC in oncology

Q&A 16:45 - 17:00

Maria Ahn Astex Pharmaceuticals, Cambridge, UK

ASTX295: designing a bone marrow sparing MDM2-p53 inhibitor

Q&A 17:20 - 17:35

DISCUSSION SESSION

Where will the next generation of cancer therapies come from – opportunities and challenges?

Steve Wedge, Newcastle University, UK; Susan Critchlow, AstraZeneca, Cambridge, UK, Erica Jackson, Scorpion Therapeutics, Boston, USA, Mark Pearson, Boehringer-Ingelheim, Austria

SUMMARY AND CLOSE